Rx (Prescription Medicine)
USD $ 120.00
Bevacizab 400mg 注射液是一种靶向治疗药物，用于治疗多种癌症。其活性成分为 Bevacizumab，是一种单克隆抗体，可抑制血管内皮生长因子（VEGF）。VEGF 是一种促进新血管生成的蛋白质，而新血管为肿瘤提供生长和转移所需。通过阻断 VEGF，Bevacizab 有助于减缓或停止肿瘤生长，并可防止肿瘤中形成新的血管。
Bevacizab 400mg 注射液适用于转移性结直肠癌、非鳞状非小细胞肺癌、胶质母细胞瘤、转移性肾细胞癌以及持续性、复发性或转移性宫颈癌的治疗。给药剂量和疗程由主治医生根据具体的癌症类型、分期以及患者的整体健康状况来确定。
常见的不良反应可能包括高血压、鼻出血、尿蛋白以及疲劳。严重的不良反应也可能发生，因此如有任何疑虑，请与您的医疗提供者讨论。Bevacizab 400mg 注射液应储存在室温并避光保存。本药必须在合格医疗专业人员的监督下使用。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Strength | |
| Brand Name | |
| Molecule | |
| Strength | 400 mg |
| Medicine Form | Injection |
| Pack Quantity | 1 Vial |
| Packaging Type | Vial |
| Medicine Type | Branded |
| Country Of Origin | India |
| Rx Status | Rx (Prescription Medicine) |
其他品牌的 Bevacizumab 400 mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
